Emerging Gene-Editing Modalities for Osteoarthritis

Int J Mol Sci. 2020 Aug 22;21(17):6046. doi: 10.3390/ijms21176046.


Osteoarthritis (OA) is a pathological degenerative condition of the joints that is widely prevalent worldwide, resulting in significant pain, disability, and impaired quality of life. The diverse etiology and pathogenesis of OA can explain the paucity of viable preventive and disease-modifying strategies to counter it. Advances in genome-editing techniques may improve disease-modifying solutions by addressing inherited predisposing risk factors and the activity of inflammatory modulators. Recent progress on technologies such as CRISPR/Cas9 and cell-based genome-editing therapies targeting the genetic and epigenetic alternations in OA offer promising avenues for early diagnosis and the development of personalized therapies. The purpose of this literature review was to concisely summarize the genome-editing options against chronic degenerative joint conditions such as OA with a focus on the more recently emerging modalities, especially CRISPR/Cas9. Future advancements in novel genome-editing therapies may improve the efficacy of such targeted treatments.

Keywords: CRISPR/Cas9; genome editing; miRNA; osteoarthritis.

Publication types

  • Review

MeSH terms

  • Animals
  • CRISPR-Cas Systems
  • Extracellular Vesicles / transplantation
  • Gene Editing / methods*
  • Genetic Therapy / methods
  • Humans
  • Mesenchymal Stem Cells
  • Osteoarthritis / genetics*
  • Osteoarthritis / therapy*
  • Regeneration